Members do not see these Ads.
Sign Up .
A pain model with a neuropathic somatosensory lesion - Mortońs neuroma
Hans Quiding, Christian Åkermark, Märta Segerdahl, Ingalill Reinholdsson, Hanna Svensson, Bror Jonzon
PAIN; Article in Press
A randomized, double-blind, three-period cross-over study was performed to characterize the sensory phenotype and pain demographics in patients with Morton’s neuroma (n=27) and to explore the effect of local administration (2 mL) of placebo and lidocaine (1 and 10mg/mL) around the neuroma. Using the pain quality assessment scale (PQAS) the highest rating was seen for unpleasant pain and intensity of deep pain and the lowest for sensitive skin. Ongoing pain was reported in 32% of patients. Patients stated mild to moderate average pain and that pain only marginally interfered with sleep. QST measurements in the innervation territory showed hypo or hyperphenomena in all patients, indicating neuropathy. There was no particular QST modality that appeared specifically affected.
Even the high dose lidocaine resulted in limited effect on nerve impulse conduction as judged by the effect on QST variables. However, both doses of lidocaine significantly reduced pain after step ups compared to placebo, indicating that lidocaine in this setting predominantly affected impulse generation and not impulse conduction. Following placebo treatment pain after step ups was similar between patients with and without hyperalgesia, indicating that presence of hyperalgesia doesn’t affect the pain intensity evoked by step ups/walking.
This pain model in Morton’s neuroma patients allows investigation of drugs in a cross-over design and provides an opportunity to explore drug effects on both pain and QST variables. The neuromas are frequently surgically removed and can be characterized in depth in vitro thereby allowing close links to be established between pathophysiology and drug effect.
Click to expand...